You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 8,008,003


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,008,003
Title:Gene expression profiling of EGFR positive cancer
Abstract: The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
Inventor(s): Baker; Joffre B. (Montara, CA), Cronin; Maureen T. (Los Altos, CA), Shak; Steve (Hillsborough, CA), Baselga; Jose (Barcelona, ES)
Assignee: Genomic Health, Inc. (Redwood City, CA)
Application Number:10/714,195
Patent Claims:1. A method for predicting the likelihood that a human colon cancer patient will exhibit a clinically beneficial patient response to treatment with cetuximab, the method comprising: a) assaying a normalized level of a predictive RNA transcript in a sample comprising ErbB1-expressing colon cancer cells obtained from said patient, wherein the predictive RNA transcript is the transcript of laminin gamma 2 (LAMC2); b) analyzing the normalized level of the LAMC2 transcript; and c) predicting the likelihood of response of the patient to treatment with cetuximab by comparing the normalized level of the LAMC2 transcript to gene expression data obtained from reference samples derived from patients with colon cancer, wherein an increased normalized level of LAMC2 RNA transcript correlates with a decreased likelihood of response to treatment with cetuximab.

2. The method of claim 1, wherein said sample is a tissue sample.

3. The method of claim 2, wherein the tissue sample is fixed, paraffin-embedded, or fresh, or frozen.

4. The method of claim 2, wherein the tissue sample is derived from fine needle, core, or other types of biopsy.

5. The method of claim 1, further comprising the step of preparing a report comprising a statement whether the patient is likely to respond to treatment with cetuximab.

6. The method of claim 1, wherein the normalized level of the LAMC2 RNA transcript is determined using an array comprising polynucleotides hybridizing to a LAMC2 gene immobilized on a solid surface.

7. The method of claim 6, wherein said polynucleotides are cDNAs.

8. The method of claim 7, wherein said cDNAs are about 500 to about 5000 bases.

9. The method of claim 6, wherein said polynucleotides are oligonucleotides.

10. The method of claim 9, wherein said oligonucleotides are about 20 to 80 bases long.

11. The method of claim 6, wherein the array comprises about 330,000 oligonucleotides.

12. The method of claim 6 wherein said solid surface is glass.

13. The method of claim 2, wherein RNA is isolated from colon cancer cells present in a fixed, paraffin-embedded tissue by a procedure comprising: (a) incubating one or more sections of said fixed, paraffin-embedded tissue at a temperature of about 56.degree. C. to 70.degree. C. in a lysis buffer, in the presence of a protease, without prior dewaxing, to form a lysis solution; (b) cooling the lysis solution to a temperature where the paraffin solidifies, thereby generating a cooled lysis solution; and (c) isolating the RNA from said cooled lysis solution.

14. The method of claim 1, further comprising the use of a kit comprising one or more of (1) extraction buffer/reagents for extracting mRNA from a sample and protocol; (2) reverse transcription buffer/reagents and protocol; and (3) quantitative polymerase chain reaction (qPCR) buffer/reagents and protocol suitable for performing the method of claim 1.

15. The method of claim 6, wherein said polynucleotides comprise modified and unmodified polynucleotides.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.